From £6.99 per month
ShareProphets
The one stop source for breaking news, expert analysis, and podcasts on fast-moving AIM and LSE listed shares

MINDING THE LSE’S BUSINESS

Join for as low as £6.99 per month

With ShareProphets’ membership, you receive:

• All premium articles

• Tom Winnifrith’s Bearcast

• Access to all the entire nearly 10 year archive

• ShareProphets Daily Newsletter

Physiomics – “trading update”, why still a balance sheet position that dare not speak its name?…

By Steve Moore | Friday 3 May 2024


Disclosure: I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from ShareProphets). I have no business relationship with any company whose stock is mentioned in this article.


Describing itself as “a leading mathematical modelling and data science company supporting the development of new therapeutics and personalised medicine solutions”, Physiomics (PYC) has issued a trading update which includes noting “a strong pipeline of potential new business” and “a high level of confidence… two large contracts… will be signed before the end of this financial year… the company would then be going into its next financial year with one of its highest ever levels of signed projects”. So what of a share price currently more than 13% lower in response at 1.3p?
You must be a registered member to read this story
ShareProphets is reader-supported journalism

Join us for free and gain access to three articles per month

Or become a member starting at £6.99 per month for all articles, the Bearcast, and our seven year archive.


Filed under:



Subscribe to our newsletter

Daily digest of our latest stories.



Search ShareProphets

Market News

Complete Coverage

Recent Comments

That Was the Week that Was

 

AAU

Ariana – Surprise!

Time left: 22:36:15